Ibnsina Pharma results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements.
Net profit208 millionEGP · +425.1% vs the same period a year earlier
Total assets28.64 billionEGP · +54.4% vs the same period a year earlier
Shareholders' equity2.03 billionEGP · +40.2% vs the same period a year earlier
Operating cash flow-1.1 billionEGP · −305.4% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q4 2024 was about 208 million EGP, up +425.1% from 39.62 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 28.64 billion EGP, and shareholders' equity about 2.03 billion EGP.
- Operating cash flow for Q4 2024 was negative at 1.1 billion EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit208 million39.62 million+425.1%
Gross profit1.42 billion688 million+106.9%
Total assets28.64 billion18.55 billion+54.4%
Total liabilities26.61 billion17.1 billion+55.6%
Shareholders' equity2.03 billion1.45 billion+40.2%
Total liabilities and equity28.64 billion18.55 billion+54.4%
Operating cash flow-1.1 billion536 million−305.4%
Investing cash flow-113 million-13.27 million−750.9%
Financing cash flow1.13 billion-116 million+1076.4%
Net change in cash-79.08 million406 million−119.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy